New climate change projections: What CMIP7 means for companies assessing climate risk
by James Balik-Meacher, Yinpeng Li, Nuzhah Tarsoo, Emma Elbaum
View post
Decarbonisation in pharma and healthcare: State of the sector 2025 report
- Post Date
- 12 August 2025
- Read Time
- 1 minute
Our State of the Sector 2025 report maps the decarbonisation commitment of 25 leading pharmaceutical companies, 17 key collaborations, and renewable energy markets across 7 regions.
This first-of-its-kind sectorial landscape helps companies and collaborations benchmark progress, align efforts, and cut through the complexity:
- All 25 companies have Scope 1 & 2 targets; over two-thirds aim for near-term reductions by 2030
- Scope 3 targets are growing, but vary widely in ambition and structure
- Supplier engagement is essential, but often complex, inconsistent, and unsupported
- Collaborations are everywhere, but risk overlap and supplier fatigue
- Data management is fragmented, creating a burden for suppliers
- Renewable energy markets are maturing but not equally across regions
- Standardising product footprinting remains a major unmet need
Uncover how leading companies are advancing climate goals, where the challenges remain, and how multi-stakeholder partnerships and renewable energy sourcing accelerate positive impact.
About the methodology:
Our research is based entirely on publicly available data for 25 of the world’s largest pharmaceutical companies, 17 collaborative initiatives, and 7 key energy markets. Data was cross-checked and initiative profiles were shared for narrative review, ensuring editorial accuracy while preserving independent analysis.
